Medtronic MDT Allowance for Doubtful Accounts Receivable (Current)
Allowance for Doubtful Accounts Receivable (Current) at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.
The official record: Medtronic’s 10-Q, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's allowance for doubtful accounts receivable (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's allowance for doubtful accounts receivable (current)?
- Medtronic (MDT) reported allowance for doubtful accounts receivable (current) of $207M in Q4 2025.
- How has Medtronic's allowance for doubtful accounts receivable (current) changed year-over-year?
- Medtronic's allowance for doubtful accounts receivable (current) increased by 1.5% year-over-year, from $204M to $207M.
- What is the long-term trend for Medtronic's allowance for doubtful accounts receivable (current)?
- Over 4 years (2021 to 2025), Medtronic's allowance for doubtful accounts receivable (current) has grown at a -4.7% compound annual growth rate (CAGR), from $241M to $199M.
- What does allowance for doubtful accounts receivable (current) mean?
- This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.